国产唑来膦酸治疗乳腺癌骨转移的临床疗效观察

邹群, 童晓文

邹群, 童晓文. 国产唑来膦酸治疗乳腺癌骨转移的临床疗效观察[J]. 实用临床医药杂志, 2011, (15): 99-101. DOI: 10.3969/j.issn.1672-2353.2011.15.036
引用本文: 邹群, 童晓文. 国产唑来膦酸治疗乳腺癌骨转移的临床疗效观察[J]. 实用临床医药杂志, 2011, (15): 99-101. DOI: 10.3969/j.issn.1672-2353.2011.15.036
ZOU Qun, TONG Xiao-wen. Clinical observation of zoledronic acid on metastatic bone of breast cancer[J]. Journal of Clinical Medicine in Practice, 2011, (15): 99-101. DOI: 10.3969/j.issn.1672-2353.2011.15.036
Citation: ZOU Qun, TONG Xiao-wen. Clinical observation of zoledronic acid on metastatic bone of breast cancer[J]. Journal of Clinical Medicine in Practice, 2011, (15): 99-101. DOI: 10.3969/j.issn.1672-2353.2011.15.036

国产唑来膦酸治疗乳腺癌骨转移的临床疗效观察

详细信息
  • 中图分类号: R737.9

Clinical observation of zoledronic acid on metastatic bone of breast cancer

  • 摘要: 目的 观察国产唑来膦酸(因力达)治疗乳腺痛骨转移的临床疗效和不良反应.方法 国产唑来膦酸4mg加入0.9%生理盐水100 mL静脉滴注15 min,1次/4周,持续治疗6个月后评估疗效及不良反应.结果 唑来膦酸治疗患者骨痛、骨转移病灶、生活活动能力的有效率分别为83.3%、66.7%、75.0%;血液指标异常例数较治疗前有所减少,异常率有下降趋势,但治疗前后比较无统计学差异;不良反应为发热1例(4.2%),肌肉荚节酸痛2例(8.3%),全身及末梢水肿1例(4.2%),经对症治疗后消失.结论 国产唑来膦酸(因力达)治疗乳腺癌骨转移疗效肯定,不良反应发生率低,是临床治疗乳腺癌骨转移的优选方法.
  • 肖峰, 高文, 吴翼伟. 45例乳腺癌患者术后全身骨显像的临床价值研究 [J]. 实用临床医药杂志, 2009(8):100.doi: 10.3969/j.issn.1672-2353.2009.15.043.
    秦继勇, 李康明, 侯字. 乳腺癌术后首发骨转移的临床研究 [J]. 现代肿瘤医学, 2009(4):669.doi: 10.3969/j.issn.1672-4992.2009.04.026.
    于世英. 恶性肿瘤骨转移的诊断与治疗 [M]. 北京:中国协和医科大学出版社, 2006.149.
    蒋爱梅, 邢海霞, 普萍. 三种乳腺癌骨转移模型复制方法比较研究 [J]. 昆明医学院学报, 2007(1):14.doi: 10.3969/j.issn.1003-4706.2007.01.004.
    Mystakidou K, Katsouda E, Parpa E. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline [J]. Medical Oncology, 2005(2):195.doi: 10.1385/MO:22:2:195.
    张伟滨. 骨转移性肿瘤的治疗策略 [J]. 实用肿瘤杂志, 2008(4):290.doi: 10.3969/j.issn.1001-1692.2008.04.002.
    Matsumoto S, Kimum S, Segawa H. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer lines [J]. Lung Cancer, 2005(1):31.doi: 10.1016/j.lungcan.2004.06.003.
    Lee SR, Gordon DH, Dugan W Jr. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion [J]. Cancer, 2004(1):36.doi: 10.1002/cncr.11892.
    Reid DM, Devogelaer J P, Saag K. Zoledronic acid and risedronate in the prevention and treatment of gluoocorticoid-in-duced osteporosis (HORIZON):a multicentre, double-blind, double-dummy, randomized controlled trail [J]. The Lancet, 2009, (9671):1253.doi: 10.1016/S0140-6736(09)60250-6.
    Parles K. Regarding ”recommendations for zoledronic acid treatment of patients with bone metastases” [J]. Oncologist, 2005(5):304.doi: 10.1634/theoncologist.10-5-304.
计量
  • 文章访问数:  120
  • HTML全文浏览量:  22
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 发布日期:  2011-12-12

目录

    /

    返回文章
    返回
    x 关闭 永久关闭